Search clinical trials for: VX-152

Total 4316 results

Vertex Pharmaceuticals Incorporated

Completed

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Small Fiber Neuropathy

United States, Netherlands, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Osteoarthritis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Pain

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Cystic Fibrosis

United States
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Spain, Australia, United Kingdom, Germany, Ireland
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Germany, Australia, France, Italy, Czechia, Austria, Greece, Sweden
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Epilepsy

United States, Germany
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
EIP Pharma Inc

Completed

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Netherlands
EIP Pharma Inc

Completed

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Alzheimer's Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Partial Epilepsy

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

Poland, Croatia, Russian Federation, Bulgaria, Czech Republic, Former Serbia and Montenegro, Slovakia, Slovenia, Ukraine
Vertex Pharmaceuticals Incorporated

Completed

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Type 1 Diabetes

United States, Italy, Canada, Switzerland, Netherlands, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Focal Segmental Glomerulosclerosis (FSGS)

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Psoriasis
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Pain

United States
Vertex Pharmaceuticals Incorporated

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (AMPLITUDE)

Proteinuric Kidney Disease

United States, Spain, Ghana, France, United Kingdom, Belgium, Brazil, Portugal, Canada, Colombia, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States

Search clinical trials for: VX-152

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations